Cantor Fitzgerald Weighs in on ALX Oncology FY2026 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of ALX Oncology in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings of ($1.52) per share for the year. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.11).

A number of other research analysts have also issued reports on ALXO. Jefferies Financial Group upgraded ALX Oncology from a “hold” rating to a “buy” rating and boosted their price target for the stock from $2.00 to $3.00 in a research report on Thursday, March 6th. Piper Sandler boosted their price objective on ALX Oncology from $8.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th. UBS Group dropped their price objective on ALX Oncology from $1.20 to $1.00 and set a “buy” rating on the stock in a research note on Wednesday, May 21st. HC Wainwright dropped their price objective on ALX Oncology from $5.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Finally, Stifel Nicolaus dropped their price objective on ALX Oncology from $3.00 to $1.50 and set a “hold” rating on the stock in a research note on Friday, March 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $3.30.

ALX Oncology Trading Down 7.8%

Shares of ALXO stock opened at $0.53 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a 1 year low of $0.41 and a 1 year high of $9.04. The stock has a fifty day moving average of $0.51 and a two-hundred day moving average of $1.04. The firm has a market capitalization of $28.50 million, a PE ratio of -0.18 and a beta of 1.16.

Institutional Trading of ALX Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC raised its position in shares of ALX Oncology by 16.8% during the first quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock worth $806,000 after purchasing an additional 186,883 shares during the period. AQR Capital Management LLC raised its position in shares of ALX Oncology by 183.6% during the first quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock worth $74,000 after purchasing an additional 77,065 shares during the period. Almitas Capital LLC raised its position in shares of ALX Oncology by 10.6% during the first quarter. Almitas Capital LLC now owns 1,353,141 shares of the company’s stock worth $843,000 after purchasing an additional 130,196 shares during the period. Nuveen LLC acquired a new stake in shares of ALX Oncology during the first quarter worth $103,000. Finally, Invesco Ltd. acquired a new stake in shares of ALX Oncology during the first quarter worth $46,000. Institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.